2'-O-methyl ATP | 30948-06-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: 2'-O-methyl ATP
• 英文别名: 2'-O-methyladenosine-5'-triphosphate；[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
• CAS: 30948-06-2
• 化学式: C₁₁H₁₈N₅O₁₃P₃
• 分子量: 521.211
• InChiKey: OARVGPYQJRLYFE-IOSLPCCCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.2
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  268
• 氢给体数：
  6
• 氢受体数：
  17

反应信息

• 作为产物：
  描述：

  N⁶-phenoxyacetyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-methyladenosine 生成 2'-O-methyl ATP
  参考文献：
  名称：

  Novel solid phase synthesis of 2'-o-methylribonucleoside 5'-triphosphates and their α-thio analogues

  摘要：

  Simple, versatile and convenient syntheses of 2'-0-methyl-ribonucleoside 5'-triphosphates have been accomplished on controlled pore glass (CPG) in good yield (>60%) using 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one (salicyl phosphorochloridite). Moderate yields were obtained for the corresponding alpha-thiotri-phosphates.

  DOI：

  10.1016/s0040-4039(00)92072-0

文献信息

• Aptamer-toxin molecules and methods for using same
  申请人：——

  公开号：US20040249130A1

  公开（公告）日：2004-12-09

  Materials and methods are provided to prepare therapeutic conjugates for the treatment of proliferative diseases. The therapeutic conjugates of the invention comprise a targeting moiety conjugated to a therapeutic moiety. The therapeutic moiety of the conjugates of the present invention have a cytotoxic effect and are useful in the treatment of proliferative diseases.

  提供了用于治疗增生性疾病的治疗结合物的材料和方法。本发明的治疗结合物包括与治疗物质结合的靶向基团。本发明的结合物的治疗物质具有细胞毒作用，并可用于治疗增生性疾病。
• Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics
  申请人：Diener John L.

  公开号：US20090105172A1

  公开（公告）日：2009-04-23

  The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2′-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands.

  本发明提供了稳定的、高亲和力的核酸配体，用于与PSMA结合。本文描述了使用2'-O-甲基取代核酸的SELEX™方法和细胞表面SELEX™方法，鉴定和制备新的、稳定的、高亲和力的PSMA配体的方法。还包括使用所述核酸配体治疗和诊断PSMA表达疾病的方法和组合物。
• Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
  申请人：Diener L. John

  公开号：US20070041901A1

  公开（公告）日：2007-02-22

  The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2′-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands.

  本发明提供了稳定的、高亲和力的核酸配体与PSMA结合。本文介绍了使用2'-O-甲基取代核酸的SELEX™方法以及细胞表面SELEX™方法鉴定和制备新型、稳定、高亲和力的PSMA配体的方法。还包括使用所述核酸配体进行治疗和诊断PSMA表达性疾病的方法和组合物。
• Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
  申请人：Archemix LLC

  公开号：EP2436391A2

  公开（公告）日：2012-04-04

  Materials and methods are provided for producing and using aptamers as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and/or VEGF receptor or any combination thereof with affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.

  本发明提供了生产和使用能与 PDGF、PDGF 异构体、PDGF 受体、VEGF 和/或 VEGF 受体或它们的任何组合以亲和力和特异性结合的抗肿瘤治疗剂的材料和方法。本发明的组合物尤其适用于实体瘤治疗，可单独使用或与已知的细胞毒药物联合使用，用于治疗实体瘤。本发明还公开了具有一个或多个嵌入或附加 CpG 基序的适配体。
• Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
  申请人：Archemix LLC

  公开号：EP2596807A1

  公开（公告）日：2013-05-29

  Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer.

  治疗补体介导的眼部疾病的方法，通过施用足以治疗眼部疾病的抑制受试者补体成分的制剂，其中，在一个选定的实施方案中，所述制剂是一种抗补体适配体，在一个优选的实施方案中，所述制剂是一种抗C5适配体。